drug combinations – Communicable Diseases Research

Potential interactions between antineoplastic agents and medicines used to treat Covid-19

Article

Published on 2022-12-012022-11-15
Journal: Journal of Oncology Pharmacy Practice [Category] 치료제,

Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2

Article

Published on 2022-10-262023-07-10
Journal: Microbiology Spectrum [Category] COVID19(2023년),

[키워드] Antiviral Calu-3 camostat Combination coronavirus DAA directly acting antiviral drug combinations Ebola host-targeting antiviral HTA molnupiravir Paxlovid SARS-CoV-2 synergy variant(s) of concern.
[DOI] 10.1128/spectrum.03331-22 PMC 바로가기

Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach

Article

Published on 2022-09-092022-11-15
Journal: Drug design, development and therapy [Category] SARS, 신약개발, 치료제,

[키워드] 3CL antiviral activity Antiviral treatment approved approved drug binding binding site carried caused Compound compounds conformational change coronavirus COVID-19 drug drug combination drug combinations Drug repurposing drug synergy Dynamics effective Efficacy enzyme Favipiravir identification in silico in vitro in vitro assays Infectious disease inhibitor inhibitory effect Ligand ligand docking M pro molecular Molecular dynamics simulation molecular dynamics simulations multiple binding sites. pandemic predicted protease Protein target Proteins provide reduced SARS-CoV-2 SARS-CoV-2 viral screened Simulation suggested synergism synergistic Toxicity Treatment treatments for COVID-19 virus
[DOI] 10.2147/DDDT.S366423 PMC 바로가기

Network approaches for modeling the effect of drugs and diseases

약물 및 질병의 영향 모델링을 위한 네트워크 접근 방식

Review

Published on 2022-07-182022-09-11
Journal: Briefings in Bioinformatics [Category] COVID19(2023년), SARS, 신약개발,

Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations

용도 변경 구충제 조합의 상승적 항 SARS-CoV-2 활성

Article

Published on 2022-06-182022-09-11
Journal: BMC Pharmacology & Toxicology [Category] COVID19(2023년), SARS, 신약개발, 치료제,

[키워드] Analysis anti-parasitic drug Anti-parasitic drugs Anti-SARS-CoV-2 Activity antiviral drug antiviral drugs approach benefit Calu Calu-3 calu-3 cells Chloroquine claimed clinical trials Combination combinations country COVID-19 pandemic demonstrated drug drug combination drug combinations drugs Economy effective Effectiveness ENhance epithelial cells evaluated Health Service highest in vitro inhibitory inhibitory concentration Ivermectin Lung epithelial cells niclosamide pandemic reduction in Repurposed drug repurposing resulting SARS-CoV-2 shown Spread synergistic synergy tested Treatment vaccination Vero E6 Vero E6 cell VERO E6 cells
[DOI] 10.1186/s40360-022-00580-8 PMC 바로가기 [Article Type] Article

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro

다양한 용도 변경 약물과 결합된 몰누피라비르는 시험관 내 인간 비강 상피에서 SARS-CoV-2 감염을 추가로 억제합니다

Article

Published on 2022-06-012022-09-11
Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제,

[키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Air-liquid interface antiviral activity Antiviral treatment antiviral treatments antivirals caused cellular Clinical efficacy clinical testing clinically Combination combinations complex Compound Concentration coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 drug drug combination drug combinations Drug repurposing effective effective antiviral treatment effort Emergency use evaluated highlighting identify Immunity in vitro in vitro model inhibit inhibiting molnupiravir nasal epithelium Potential treatment Repurposed drug SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication selected severe acute respiratory syndrome Coronavirus short duration tested the vaccine These data Treatment Vaccine variant worldwide pandemic
[DOI] 10.1016/j.biopha.2022.113058 PMC 바로가기 [Article Type] Article

Machine Learning Applications in Drug Repurposing

약물 용도의 기계 학습 응용 프로그램

Review

Published on 2022-03-012022-08-31
Journal: Interdisciplinary sciences, computational life sci [Category] SARS, 신약개발,

Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study

article

Published on 2022-03-012024-09-02
Journal: Clinical Hypertension [Category] 대상포진,

[키워드] amlodipine circadian rhythm drug combinations essential hypertension telmisartan
[DOI] 10.1186/s40885-021-00184-0 PMC 바로가기 [Article Type] article

Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence

그래프 신경망을 사용하여 COVID-19에 대한 약물 용도 및 여러 증거 조화

Article

Published on 2021-11-302022-08-31
Journal: Scientific Reports [Category] 신약개발, 임상, 치료법, 치료제,

[키워드] 2019 novel coronavirus 2019 novel coronavirus disease acetaminophen albuterol approach Aspirin atorvastatin Azithromycin candidate drug candidate drugs clinical trial collected conducted coronavirus disease COVID-19 COVID-19 knowledge COVID-19 patient COVID-19 treatment demonstrated disease drug drug combination drug combinations Drug development Drug repurposing drugs Efficacy Evidence facilitate FDA approval Genetic highlight host genes in vitro integration Interaction interactions Knowledge graph Novel coronavirus novel coronavirus disease outbreak pandemic Pathways Phenotypes profiles Research Treatment Virtual screening virus was used
[DOI] 10.1038/s41598-021-02353-5 PMC 바로가기 [Article Type] Article

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials

Article

Published on 2021-11-202022-10-31
Journal: Cancers [Category] COVID-19,

[키워드] adverse effect adverse event AEs anticancer approved drugs cancer patient Cancer patients clinical clinical trial clinical trials cohort study Compound compounds COVID and cancer COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines development division drug drug combinations early-phase clinical trials Efficacy Efficacy and safety enrolled Enrollment European first dose General population Immune checkpoint inhibitors Immunotherapy include investigated Local Mild moderate MOST mRNA New novel immunotherapy Patient Patients with cancer phase one trial profiles question receive receiving required retrospective Safe Safety safety profile SARS-CoV-2 second dose simple solid tumors Support systemic AEs targeted therapy the patient the vaccine treated Treatment Trial trials Vaccine
[DOI] 10.3390/cancers13225829 PMC 바로가기 [Article Type] Article